Sombrevin

Propanidid (Sombrevin; Fabantol) is a γ-aminobutyric acid type A (GABAA) receptor agonist and a short-acting non-barbiturate general anesthetic agent. Propanidid can decrease the arterial pressure[1][2].

Signaling Pathways >> Membrane Transporter/Ion Channel >> GABA Receptor

Research Areas >> Neurological Disease

Signaling Pathways >> Neuronal Signaling >> GABA Receptor

GABAA receptor[1]

Propanidid (Sombrevin) (3-5 mg/kg; injected into the femoral vein; single dosage) changes the orientation tuning of 58 visual cortex neurons[3]. Animal Model: Adult cats (immobilized by D-tubocurarine)[3] Dosage: 3-5 mg/kg Administration: Injected into the femoral vein; single dosage Result: A reliable change of the preferable orientation by 47.6 ± 5.6 degrees took place in 60% of 58 primary visual cortex neurons, while in the remaining cells it was stable in all stages of anaesthesia. The width of the orientation tuning changed reliably by 65.2 ± 6.7 degrees on the average in 55% of neurons, while in 31% of neurons the tuning acuteness was worse, but in 24% it was sharper. The preferable orientation, the width of the tuning and the frequency of the neuron discharge as a rule recovered in 30 min after the beginning of the anaesthesia.

MOLECULAR FORMULA :

C18-H27-N-O5

MOLECULAR WEIGHT :

337.46

WISWESSER LINE NOTATION :

3OV1R CO1 DO1VN2&2

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Intravenous

SPECIES OBSERVED :

Human

DOSE/DURATION :

5 mg/kg

TOXIC EFFECTS :

Behavioral - general anesthetic Biochemical - Metabolism (Intermediary) - histamines (including liberation not immunochemical in origin)

REFERENCE :

BJANAD British Journal of Anesthesia. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1923- Volume(issue)/page/year: 45,1097,1973

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

>10 gm/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 18,185,1971

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intravenous

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

81 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

AASXAP Acta Anaesthesiologica Scandinavica, Supplementum. (Munksgaard International Pub., POB 2148, DK-1016 Copenhagen K, Denmark) No.1- 1959- Volume(issue)/page/year: 17,21,1965

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intravenous

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

113 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 19,845,1980

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intravenous

SPECIES OBSERVED :

Mammal - dog

DOSE/DURATION :

80 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

AASXAP Acta Anaesthesiologica Scandinavica, Supplementum. (Munksgaard International Pub., POB 2148, DK-1016 Copenhagen K, Denmark) No.1- 1959- Volume(issue)/page/year: 17,21,1965

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intravenous

SPECIES OBSERVED :

Mammal - cat

DOSE/DURATION :

80 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

AASXAP Acta Anaesthesiologica Scandinavica, Supplementum. (Munksgaard International Pub., POB 2148, DK-1016 Copenhagen K, Denmark) No.1- 1959- Volume(issue)/page/year: 17,21,1965

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intravenous

SPECIES OBSERVED :

Rodent - rabbit

DOSE/DURATION :

75 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

AASXAP Acta Anaesthesiologica Scandinavica, Supplementum. (Munksgaard International Pub., POB 2148, DK-1016 Copenhagen K, Denmark) No.1- 1959- Volume(issue)/page/year: 17,21,1965 ** REPRODUCTIVE DATA **

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Intravenous

DOSE :

1200 mg/kg

SEX/DURATION :

female 1-60 day(s) after conception

TOXIC EFFECTS :

Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Effects on Newborn - physical

REFERENCE :

NYSJAM New York State Journal of Medicine. (Medical Soc. of the State of New York, POB 5405, Lake Success, NY 11042) V.1- 1901- Volume(issue)/page/year: 64,2177,1964